Compound 506U78 (NSC 686673) [nelarabine] in Patients With Relapsed or Refractory T-Cell ALL [acute lymphoblastic leukaemia] or T-Cell Lymphoblastic Lymphoma
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2013
At a glance
- Drugs Nelarabine (Primary)
- Indications Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 05 Nov 2007 Status changed from in progress to completed.
- 31 Oct 2006 Status change
- 07 Sep 2005 New trial record.